AU2003292888A1 - Pharmaceutical combinations of phthalazine vegf inhibitors and benzamide hdac inhibitors - Google Patents

Pharmaceutical combinations of phthalazine vegf inhibitors and benzamide hdac inhibitors

Info

Publication number
AU2003292888A1
AU2003292888A1 AU2003292888A AU2003292888A AU2003292888A1 AU 2003292888 A1 AU2003292888 A1 AU 2003292888A1 AU 2003292888 A AU2003292888 A AU 2003292888A AU 2003292888 A AU2003292888 A AU 2003292888A AU 2003292888 A1 AU2003292888 A1 AU 2003292888A1
Authority
AU
Australia
Prior art keywords
inhibitors
phthalazine
pharmaceutical combinations
vegf
benzamide hdac
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003292888A
Other languages
English (en)
Other versions
AU2003292888A8 (en
Inventor
Marion Gansmayer
Christoph Herold
Matthias Ocker
Detlef Schuppan
Karl-Heinz Thierauch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Publication of AU2003292888A8 publication Critical patent/AU2003292888A8/xx
Publication of AU2003292888A1 publication Critical patent/AU2003292888A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2003292888A 2002-12-27 2003-12-11 Pharmaceutical combinations of phthalazine vegf inhibitors and benzamide hdac inhibitors Abandoned AU2003292888A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP02090431 2002-12-27
EP02090431.4 2002-12-27
EP03090061 2003-03-12
EP03090061.7 2003-03-12
PCT/EP2003/014071 WO2004058234A2 (en) 2002-12-27 2003-12-11 Pharmaceutical combinations of phthalazine vegf inhibitors and benzamide hdac inhibitors

Publications (2)

Publication Number Publication Date
AU2003292888A8 AU2003292888A8 (en) 2004-07-22
AU2003292888A1 true AU2003292888A1 (en) 2004-07-22

Family

ID=32683819

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003292888A Abandoned AU2003292888A1 (en) 2002-12-27 2003-12-11 Pharmaceutical combinations of phthalazine vegf inhibitors and benzamide hdac inhibitors

Country Status (4)

Country Link
EP (2) EP1738752A1 (https=)
JP (1) JP2006514991A (https=)
AU (1) AU2003292888A1 (https=)
WO (1) WO2004058234A2 (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6897220B2 (en) 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
CN101851173A (zh) 2001-09-14 2010-10-06 梅特希尔基因公司 组蛋白脱乙酰化酶抑制剂
US7868204B2 (en) 2001-09-14 2011-01-11 Methylgene Inc. Inhibitors of histone deacetylase
EP1641759B1 (en) * 2003-07-07 2014-03-12 Merck Patent GmbH Malonamide derivatives
WO2005030705A1 (en) 2003-09-24 2005-04-07 Methylgene, Inc. Inhibitors of histone deacetylase
US7253204B2 (en) 2004-03-26 2007-08-07 Methylgene Inc. Inhibitors of histone deacetylase
SE0401790D0 (sv) * 2004-07-07 2004-07-07 Forskarpatent I Syd Ab Tamoxifen response in pre- and postmenopausal breast cancer patients
EP1824831A2 (en) * 2004-12-16 2007-08-29 Takeda San Diego, Inc. Histone deacetylase inhibitors
CN101163690A (zh) 2005-04-20 2008-04-16 默克公司 苯并噻吩异羟肟酸衍生物
EP1874294A4 (en) 2005-04-20 2010-12-01 Merck Sharp & Dohme BENZOTHIOPHENO HYDROXAMIDIC DERIVATIVES WITH CARBAMATE, UREA, AMID AND SULPHONAMIDE SUBSTITUTIONS
CA2605110A1 (en) 2005-04-20 2006-11-02 Merck & Co., Inc. Benzothiophene derivatives
EP1896436A2 (en) 2005-05-11 2008-03-12 Takeda San Diego, Inc. Histone deacetylase inhibitors
CA2612420A1 (en) 2005-06-24 2007-01-04 Merck & Co., Inc. Modified malonate derivatives
EA200800321A1 (ru) 2005-07-14 2008-06-30 Такеда Сан Диего, Инк. Ингибиторы гистондеацетилазы
AR057579A1 (es) 2005-11-23 2007-12-05 Merck & Co Inc Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac)
JP2009120486A (ja) * 2005-12-05 2009-06-04 Mitsubishi Pharma Corp 核内オーファン受容体の新規活性化剤及びその用途
WO2007100657A2 (en) 2006-02-28 2007-09-07 Merck & Co., Inc. Inhibitors of histone deacetylase
CN101466670B (zh) 2006-04-07 2013-04-17 梅特希尔基因公司 组蛋白脱乙酰酶抑制剂
CA2649861A1 (en) 2006-04-26 2007-11-08 Merck & Co., Inc. Disubstituted aniline compounds
EP2023924B1 (en) 2006-05-18 2016-08-03 Merck Sharp & Dohme Corp. Aryl-fused spirocyclic compounds
EP2049124A4 (en) 2006-07-20 2010-02-10 Merck & Co Inc PHOSPHOR DERIVATIVES AS HISTONDEACETYLASE HEMMER
AU2008269154B2 (en) 2007-06-27 2014-06-12 Merck Sharp & Dohme Llc 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
EP2170339B1 (en) 2007-06-27 2014-10-15 Merck Sharp & Dohme Corp. Pyridyl and pyrimidinyl derivatives as histone deacetylase inhibitors
EP2060565A1 (en) 2007-11-16 2009-05-20 4Sc Ag Novel bifunctional compounds which inhibit protein kinases and histone deacetylases
AU2009289649B2 (en) 2008-09-03 2016-05-05 Biomarin Pharmaceutical Inc. Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors
EP2429987A4 (en) * 2009-05-15 2012-10-03 Korea Res Inst Chem Tech AMIDE COMPOUND, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
US8912184B1 (en) 2010-03-01 2014-12-16 Alzheimer's Institute Of America, Inc. Therapeutic and diagnostic methods
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US9540395B2 (en) 2011-02-28 2017-01-10 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
WO2014160221A1 (en) 2013-03-13 2014-10-02 The General Hospital Corporation Photoswitchable hdac inhibitors
DK2970139T3 (en) 2013-03-15 2018-08-13 Biomarin Pharm Inc HDAC inhibitors
TWI635077B (zh) * 2016-08-11 2018-09-11 行政院原子能委員會核能研究所 針對腫瘤診斷與治療之組織蛋白去乙醯酶抑制劑（ＨＤＡＣｉ）ＰＥＴ造影化合物與類似物，及其製造方法
US11208382B2 (en) * 2017-07-28 2021-12-28 Hangzhou Solipharma Co., Ltd. Entinostat-containing compound, crystal form of compound thereof, and preparation method therefor and pharmaceutical composition thereof
US12522587B2 (en) 2018-05-04 2026-01-13 Remedy Plan, Inc. Cancer treatments targeting cancer stem cells
CA3143188A1 (en) * 2019-06-13 2020-12-17 Dana-Farber Cancer Institute, Inc. Hdac3 catalytic inhibitor development and uses thereof
EP4055008A1 (en) 2019-11-06 2022-09-14 Remedy Plan, Inc. Cancer treatments targeting cancer stem cells
HRP20251279T1 (hr) 2020-04-30 2025-12-05 Great Novel Therapeutics Biotech & Medicals Corporation Inhibitori histon deacetilaze za imunomodulaciju u tumorskom mikrookruženju
CN114957132A (zh) * 2021-02-20 2022-08-30 中国科学院上海药物研究所 含s构型的氨基苯甲酰胺基哒嗪酮类化合物、其制备方法、药物组合物及应用
CN113200908B (zh) * 2021-04-09 2022-07-19 南华大学 一种含叔胺的邻氨基苯甲酰胺类化合物及其制备与应用
CN115703736B (zh) * 2021-08-04 2025-05-16 中国海洋大学 靶向于hdac和nad合成的多靶点抑制剂及其用途
KR102743956B1 (ko) * 2021-10-08 2024-12-17 아주대학교산학협력단 히스톤 탈아세틸화효소 억제제를 포함하는 대사성 질환의 예방, 개선 또는 치료용 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2097788B (en) 1981-04-03 1985-04-24 Lilly Co Eli Benzothiophene compounds and process for preparing them
DE3121152A1 (de) 1981-05-22 1982-12-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen "verwendung der kombination eines aromatase-hemmers mit einem antiandrogen zur prophylaxe und therapie der prostatahyperplasie"
US5053405A (en) 1990-06-21 1991-10-01 Sterling Drug Inc. Antiandrogenic sulfonylsteroidothiazoles
SE9300971D0 (sv) * 1993-03-24 1993-03-24 Jan Wadstein Hudvaardskomposition
US6174905B1 (en) 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
GB0111078D0 (en) * 2001-05-04 2001-06-27 Novartis Ag Organic compounds
PL367349A1 (en) * 2001-09-12 2005-02-21 Novartis Ag Use of 4-pyridylmethylphthalazines for cancer treatment
US20040266779A1 (en) * 2001-09-27 2004-12-30 Anderson Kenneth C. Use of c-kit inhibitors for the treatment of myeloma
WO2003059354A2 (en) * 2001-12-21 2003-07-24 Bayer Pharmaceuticals Corporation Anti-angiogenesis combination therapies comprising pyridazine or pyridine derivatives

Also Published As

Publication number Publication date
WO2004058234A2 (en) 2004-07-15
AU2003292888A8 (en) 2004-07-22
JP2006514991A (ja) 2006-05-18
WO2004058234A3 (en) 2006-01-12
EP1738752A1 (en) 2007-01-03
EP1641458A2 (en) 2006-04-05

Similar Documents

Publication Publication Date Title
AU2003292888A1 (en) Pharmaceutical combinations of phthalazine vegf inhibitors and benzamide hdac inhibitors
AU2003221786A1 (en) Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
AU2003303128A1 (en) Inhibitors and methods of use thereof
IL164006A0 (en) Inhibitors of histone deacetylase
IL164659A0 (en) Inhibitors of histone deacetylase
AU2002243402A1 (en) Inhibitors of histone deacetylase
AU2003219595A1 (en) Alpha,Beta-UNSATURATED HYDROXAMIC ACID DERIVATIVES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS
AU2003275311A1 (en) Solid micro-perforators and methods of use
AU2003288902A1 (en) Microcapsules and methods of use
PL374962A1 (en) Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor
AU2002352795A1 (en) Aromatic sulfone hydroxamic acids and their use as protease inhibitors
AU2002250401A1 (en) Histone deacetylase inhibitors
AU2002306624A1 (en) Heterocyclic analgesic compounds and methods of use thereof
AU2002315229A1 (en) Histone deacetylase and methods of use thereof
AU2002337913A1 (en) Glycosulfopeptide inhibitors and methods of use thereof
AU2003258942A1 (en) Imidazolidinedione-derivatives and their use as metalloproteinase inhibitors
AU2002342889A1 (en) Anthranilic acid amides and pharmaceutical use thereof
AU2003290583A1 (en) Aromatic sulfone hydroxamic acids and their use as protease inhibitors
AU2003258941A1 (en) Metalloproteinase inhibitors and intermediates for preparation thereof
AU2003251513A1 (en) Rsk inhibitors and therapeutic uses thereof
AU2003279188A1 (en) Hydroxamate derivatives of non-steroidal anti-inflammatory drugs
AU2003287802A1 (en) Palpometer and methods of use thereof
AU2003300800A1 (en) Heteroarylsulfonylmethyl hydroxamic acids and amides and their use as protease inhibitors
AU2003294941A1 (en) Combinations of a vanilloid antagonist and an nsaid for the treatment of pain
AU2003285686A1 (en) Glycoisoforms of adiponectin and uses thereof

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase